Generic and Biosimilar Medicines Industries Welcome Ontario Government’s Investment in Next Phase of Life Sciences Strategy

The CGPA and its Biosimilars Canada division welcome the Ontario government’s announcement of a $146 million investment in the next phase of its Life Sciences Strategy to help position the province as a global leader in life sciences. L’article Generic and Biosimilar Medicines…

ScopeUp collects Ontario and national pharmacy practice updates and links every item to its source. Verify details against the source document before changing workflows.